Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Sandoz
Sandoz
Sandoz Nabs FDA Approvals for First Two Biosimilars for Amgen’s Denosumab
BioSpace
Wed, 03/6/24 - 11:29 am
Sandoz
biosimilars
FDA
Amgen
denosumab
Prolia
Jubbonti
Xgeva
Wyost
Sandoz completes acquisition of ranibizumab biosimilar
Healio
Mon, 03/4/24 - 11:52 pm
Sandoz
ranibizumab
Coherus Biosciences
Cimerli
Sandoz will pay $265m to settle price fixing case in US
Pharmaphorum
Thu, 02/29/24 - 09:44 am
Sandoz
price fixing
legal
Pennsylvania
Amid tough generics market, Sandoz to lay off 213 and shutter Eon Labs plant in North Carolina
Fierce Pharma
Thu, 02/8/24 - 09:57 pm
Sandoz
layoffs
North Carolina
generics
drug manufacturing
Sandoz makes its first post-spinout acquisition
Pharmaphorum
Mon, 01/22/24 - 11:12 am
Sandoz
M&A
Coherus
biosimilars
AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players
Fierce Pharma
Wed, 11/22/23 - 11:39 am
AbbVie
Rinvoq
patents
legal
Sandoz
Sun Pharma
Intas Pharmaceuticals
Novartis' Sandoz dips on debut after lower than expected valuation
Reuters
Wed, 10/4/23 - 09:43 am
Novartis
Sandoz
spinoffs
Novartis confirms Sandoz spin-off for October 4, 2023
Reuters
Mon, 09/25/23 - 07:45 pm
Novartis
Sandoz
spinoffs
Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara
BioSpace
Tue, 09/12/23 - 10:40 am
Sandoz
Samsung Bioepis
biosimilars
JNJ
Stelara
Novartis updates on Sandoz finances ahead of spin-off
Pharmaphorum
Tue, 09/5/23 - 11:18 am
Novartis
Sandoz
spinoffs
generics
biosimilars
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
BioSpace
Fri, 08/25/23 - 09:53 am
Biogen
Sandoz
FDA
biosimilars
MS
multiple sclerosis
Tysabri
Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation
Biopharma Reporter
Mon, 08/21/23 - 06:50 pm
Novartis
Sandoz
spinoff
biosimilars
generics
Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4
Fierce Pharma
Fri, 08/18/23 - 11:29 am
Novartis
Sandoz
spinoffs
generics
biosimilars
Sandoz plans to enter the Eylea biosimilar race
Clinical Trials Arena
Tue, 08/15/23 - 10:03 am
Sandoz
generics
biosimilars
Eylea
Novartis
wet age-related macular degeneration
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
Thu, 07/27/23 - 10:25 am
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
7 companies are rolling out Humira biosimilars
Drugstore News
Wed, 07/12/23 - 09:44 am
AbbVie
Humira
biosimilars
Boehringer Ingelheim
Organon
Samsung Bioepsis
Sandoz
Fresenius Kabi
Celltrion
Coherus Biosciences
Biocon
Sanofi blocks Sandoz's Jevtana generic in patent win
Fierce Pharma
Fri, 06/30/23 - 10:16 am
Sanofi
Jevtana
generics
Sandoz
prostate cancer
legal
Sandoz targets barriers to biosimilar accessibility with latest initiative
Pharmaceutical Technology
Thu, 06/15/23 - 07:00 pm
Sandoz
Novartis
patient access
biosimilars
Sandoz hitches its wagon to biosimilars, predicting $3B in sales from pipeline products over next 5 years
Fierce Pharma
Thu, 06/8/23 - 09:29 pm
Novartis
Sandoz
generics
biosimilars
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »